Venture Investing
Investing in PsiQuantum | How to Buy Pre-IPO Shares
Add Securities.io to your preferred sources on Google
Securities.io may receive compensation when you use links to products we review. This does not influence our editorial evaluations. We are not a registered investment adviser; this is not investment advice. Read our affiliate disclosure.
PsiQuantum is a private quantum-computing company developing a fault-tolerant, utility-scale system based on photonic qubits and semiconductor manufacturing methods. Its strategy emphasizes building a large system capable of error-corrected commercial workloads rather than a succession of small machines.
The technical ambition and public-sector partnerships are substantial, but private shares carry unusually high execution, capital, timing, concentration, and liquidity risk.
What Is PsiQuantum?
PsiQuantum was founded in 2016 by Jeremy O’Brien, Terry Rudolph, Mark Thompson, and Pete Shadbolt. The company uses silicon photonics, single-photon components, cryogenic systems, control electronics, and quantum error correction to pursue a large fault-tolerant computer.
Business Model and Key Products
The company has announced major projects in Australia and Illinois. Government incentives, site commitments, and research contracts can support execution but are not the same as equity financing and are not included in the funding chart.
PsiQuantum Funding and Valuation History
PsiQuantum’s latest verified equity financing is its September 2025 Series E, which raised $1 billion at a $7 billion valuation. The selected history reconciles the named Series A through E rounds without counting government packages as venture funding.
PsiQuantum Selected Funding Events
Verified disclosed equity financing, USD millions; government funding packages excluded.
Verified Aug. 25, 2026
2016–2020 · $0–$250M
2021–2025 · $0–$1B
| Date | Round / type | Funding Raised | Reported valuation | Selected investors | Source |
|---|---|---|---|---|---|
| Sep. 10, 2025 | Series E | $1B | $7B | BlackRock; Temasek; Baillie Gifford; NVIDIA; Macquarie; others | PsiQuantum |
| July 27, 2021 | Series D | $450M | $3.15B | BlackRock; Baillie Gifford; M12; Blackbird Ventures; Temasek; others | PsiQuantum |
| Apr. 2, 2020 | Series C | $215M | More than $1B reported | Atomico; Blackbird Ventures; Founders Fund; Playground; others | TechCrunch |
| Sep. 2017 | Series B | $51.5M | Not disclosed | Atomico; Playground Global; other investors | Financial Times |
| 2016 | Series A | $13.5M | Not disclosed | Blackbird Ventures; Playground Global; other investors | Australian Financial Review |
Methodology: The selected total is $1.73 billion across the five named rounds shown. The April 2020 Series C is used instead of overlapping contemporaneous estimates. Government incentives, site-development packages, research grants, contracts, and undisclosed capital are excluded from the total.
Investment Case
The investment case depends on whether PsiQuantum can integrate photonics, manufacturing, error correction, and system engineering into a useful fault-tolerant machine on an economically viable timeline.
Fault-Tolerant Focus
PsiQuantum is designing around the scale and error correction needed for commercially meaningful workloads.
Semiconductor Manufacturing
Photonic components may benefit from established high-volume semiconductor fabrication methods.
Government Partnerships
Projects in Australia and Illinois provide sites, incentives, ecosystem support, and strategic validation.
Deep Technical Team
The company combines expertise in quantum information, photonics, packaging, cryogenics, and systems engineering.
Key Risks
Technical Execution
A fault-tolerant photonic computer requires many interdependent breakthroughs and extremely reliable components.
Timeline Risk
Commercially useful systems may arrive later than expected, delaying revenue and requiring more capital.
Capital Intensity
Fabrication, facilities, cryogenics, networking, and system integration may consume substantial additional funding.
Competing Architectures
Superconducting, trapped-ion, neutral-atom, silicon-spin, and other photonic approaches may progress faster.
Policy and Concentration Risk
Large projects depend on government support, key suppliers, sites, and manufacturing relationships.
Liquidity and Valuation
Private shares may be unavailable, difficult to value, and subject to dilution and transfer restrictions.
How to Buy PsiQuantum Pre-IPO Shares
- Confirm that PsiQuantum remains private. Check for an SEC registration statement, a confirmed listing, or a material corporate transaction before pursuing private shares.
- Confirm your eligibility. Many late-stage secondary offerings use Regulation D and are limited to accredited investors. Individuals may qualify through net worth, income, or specified professional criteria.
- Find a live opportunity. Search registered private-market platforms or work with a qualified broker. A platform’s inclusion here does not mean it currently lists PsiQuantum.
- Review the security and vehicle. Determine whether the offer provides direct company shares or an interest in an SPV. Review share class, liquidation preferences, voting rights, information rights, and the investment manager.
- Evaluate price and fees. Compare the offered price and implied valuation with the latest financing while accounting for platform fees, carried interest, SPV expenses, and security rights.
- Review transfer and exit restrictions. Examine company consent requirements, rights of first refusal, holding periods, and what happens if an IPO or acquisition never occurs.
Accredited-investor criteria: Under current SEC criteria, an individual may qualify through net worth above $1 million excluding the primary residence; income above $200,000 individually or $300,000 with a spouse or partner in each of the prior two years with a reasonable expectation of the same; or certain professional criteria. Review the SEC criteria.
Where to Buy PsiQuantum Pre-IPO Shares
Availability on private marketplaces changes with seller supply, company transfer restrictions, jurisdiction, and investor eligibility. Always verify the live offering rather than assuming that PsiQuantum shares are available.
MicroVentures
MicroVentures facilitates primary and secondary private-company offerings. Eligibility, minimums, fees, investment structure, and availability vary by offering; Regulation D opportunities are limited to accredited investors.
View Available Private-Market Opportunities
PsiQuantum availability is not guaranteed. Review the specific offering documents before investing.
| Platform | Typical access model | What to verify |
|---|---|---|
| StartEngine Private | Late-stage private-company offerings | Current issuer availability, eligibility, minimum, fees, and vehicle structure |
| Forge Global | Private-company secondary marketplace and brokerage | Seller availability, accreditation, price, share class, and transaction costs |
| EquityZen | Private-company offerings that may use pooled vehicles | SPV terms, fees, minimum, economic rights, and transfer conditions |
| Rainmaker Securities | Broker-assisted private-company transactions | Security source, broker fees, settlement, and company approval |
| Hiive | Private-market bids, asks, and facilitated trades | Indicative versus executable pricing, fees, and transfer restrictions |
| EquityBee | Employee stock-option financing and related exposure | Contract structure, payoff terms, fees, and whether exposure is direct or indirect |
| Augment | Private-market transaction platform | Counterparty, price, share class, fees, and settlement terms |
PsiQuantum Valuation and IPO Outlook
The September 2025 Series E valued PsiQuantum at $7 billion. The company remains private, and we found no confirmed SEC registration statement, exchange, ticker, or IPO date.
Prospective investors should separate venture financing from government project values and commercial contracts. The security offered, liquidation preferences, dilution protection, information rights, and transfer restrictions are central to valuation.
Investing in PsiQuantum Pre-IPO Shares | Conclusion
PsiQuantum offers concentrated exposure to an ambitious photonic approach to fault-tolerant quantum computing, supported by major investors and public-sector projects.
The opportunity is matched by extreme technical, capital, schedule, and commercialization risk. Investors should assume a long horizon, additional dilution, and limited liquidity while evaluating the exact security being offered.
Explore other pre-IPO investment opportunities.
Primary and Supporting Sources
- PsiQuantum Series E announcement
- PsiQuantum Series D announcement
- TechCrunch reporting on Series C
- Financial Times reporting on Series B
- PsiQuantum company overview
Disclaimer: This article is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Private securities can result in the loss of the entire investment and may remain illiquid indefinitely. Company and marketplace availability can change without notice. Verify all terms in the applicable offering documents and consult qualified professional advisers where appropriate.
